- 100% recycled rPET is made entirely from plastic bottles. Once they have been separated out from other waste, the bottles are shredded, washed and made into pellets. Food-grade, recyclable rPET has the same technical characteristics as virgin PET. It is used to produce bottles designed for liquids (such as syrups and drinkable solutions) and pill dispensers for solid forms (such as gel capsules, soft capsules, tablets and gummies). The range comprises 16 bottles ranging in volume from 60 ml to 1L and five pill dispensers ranging from 50 ml to 250 ml.
- Bio-sourced PE is a plant-based plastic derived from sugar-cane residue and used to produce a range of 13 pill dispensers designed for solid forms (gel capsules, soft capsules, tablets and gummies) ranging in volume from 30 to 250 ml.
- Mass Balance PE comes from recycled materials and biomass, combining recycled and bio-sourced raw materials with others derived from fossil fuels. It too is used to produce a range of 13 pill dispensers designed for solid forms (gel capsules, soft capsules, tablets and gummies) ranging in volume from 30 to 250 ml.
Reducing the impact of plastic materials
"As a manufacturer of medical devices and primary and secondary packaging made from polymers, we are well aware that every decision we make may have a more or less significant impact on the environment. For many years, our production facilities have been optimised to avoid product losses, consume as little energy as possible and recycle rejects. Today, we are embarking on a new stage, by sourcing recycled or bio-sourced materials. Consumers, and therefore our customers, are expressing a clear desire for reducing the use of plastic. While we cannot eradicate it completely, since it remains an essential product for certain applications, in particular health, with qualities that are difficult to compete with - it is light, affordable, transformable, robust and recyclable - we can improve it. One of our members of staff has been tasked with identifying alternatives we can use in order to test them quickly. The three product families we have already selected have required a significant level of work to bring them into production and we are currently running other promising trials," comments Jérôme Empereur, CEO of SGH Healthcaring.